Diabetes Flashcards

(70 cards)

1
Q

Pancreatic islet innervation

A

PSNS: vagus, ACh mediated –> increase insulin release
SNS: Post-ganglionic fibers originating in celiac ganglion (foregut)
- NE mediated –> inhibit insulin secretion
- E from adrenal gland –> neurohormonal action to decrease insulin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Type 1 DM pathophys

A

Genetic + immune + environmental factors –> cell destruction
Strong genetic correlation with certain HLA loci, associated with other autoimmune diseases
- HLA-DR, HLA-DQ alleles
-Polygenic
- 50% concordance in identical twins
Viruses: coxsackie, mumps, rubella
Lymphocyte infiltration –> islet cell destruction
- islet cell Ab present in up to 60-85% of cases (best predictor of disease)
- up to 69% have Ab against insulin

Possibilities:

  • molecular mimicry
  • bystandar activation - nonspecific infection causes cytokine release into pancreas
  • beta cell apoptosis

80% beta cell destruction –> symptomatic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Type 2 DM pathophys

A

Impaired insulin secretion AND peripheral insulin resistance
>90% concordance in identical twins - strong genetic component
1) Glucose tolerance normal, insulin resistance high - compensation by increased insulni secretion
2) Beta cells unable to maintain hyperinsulinemic state –> glucose intolerance, diabetes

Associated with obesity, particularly intraabdominal obesity
Resistance involves genetic and/or acquired post-receptor defects in insulin action

Rare (5%) , single gene mutation = “mature onset diabetes of the young”
genes that regultae beta cell mass or function - MODY2, glucokinase, impaired insulin secretion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Causes of progressive loss of insulin secretion in type 2 diabetes

A

glucose toxicity and lipotoxicity to beta cells
beta cell exhaustion/stress
pro-inflammatory cytokines: beta cells during hyperglycemic stress make pro-inflammatory cytokines
Islet myloid deposits: toxic amyloid deposits composed of islet amyloid polypeptide (IAPP) found in most T2D patients

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Nesidioblastosis

A

= hyperinsulinemic hypoglycemia
excessive function of pancreatic beta cells with abnormal microscopic appearance
aka congenital hyperinsulinism
islet cell enlargement, islet cell dysplasia, beta cell hyperplasia/budding from ductal epithelium
Proliferation of islet cells from pancreatic ducts –> hypoglycemia and hyperinsulinemia in infants and newborns

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Insulinoma

A

Tumour of the pancreas
Symptoms of hypoglycemia - improved by eating
tx surgery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Type 1 DM onset and epidemiology

A

<30 yrs old, acute
Caucasians
Rare in blacks, hispanics, asians
5-10% of DM

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Type 2 DM onset and epidemiology

A

Usually >40, gradual
Black, hispanics, Asians, aboriginals
>90% of DM
5% of population, and increasing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Syndrome X

A

etiology of type 2 DM

central obesity, hyperlipidemia, hyperinsulinemia, HTN, diabetes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Type 1 DM clinical features

A

normal to wasted body
polydipsia
polyuria
hyperphagia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Type 2 DM clinical features

A
overweight with central obesity
HONDA patient
don't usually get ketosis
often normal insulin levels
acanthosis nigricans (dark pigmentation)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Acute complications of DM

A
Diabetic ketoacidosis (Type 1)
Hyperglycemic hyperosmolar state (type 2, elderly)
Hypoglycemia
Myocardial infarction
Stroke
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Diabetic ketoacidosis pathophys

A

Hyperglycemia leading to:

  • osmotic diuresis - loss of electrolytes
  • ileus from electrolyte abnormalities - voimting
  • polyuria, polydipsia, dehydration, hypotension, tachycardia and peripheral circulatory failure
  • decrease intravascular volume –> aldosterone secretion via RAAS –> potassium loss

Upregulation of glucagon

  • increased lipolysis and ketogenesis –> accumulation (beta-hydroxybutyrate)
  • metabolic acidosis + compensatory hyperventilation
  • acidosis –> K out of cells, then lost into urine

+ insulin treatment –> activates Na/K pump, K sequestered into cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Hyperglycemic hyperosmolar state pathphys

A

Residual activity in patients –> lipolysis not activated, no ketoacidosis
Ppt factor = increased insulin resistance triggered by illness/drugs
Major problem = extreme dehydration secondary to osmotic diuresis
- glucose level >45
- contraction of blood volume - can become hypoxic - lactic acidosis may develop due to anaerobism
- sodium concentrations may become elevated secondary to diuresis
- confusion and lethargy as serum osmolality >300; coma >340

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Chronic complications of DM (categories)

A
vascular
renal
eye
neurologic
skin
infections
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Chronic complications of DM - pathogenesis

A

Non-enzymatic glycosylation of proteins. 3 stages:
1) Schiff base formation (reversible)
2) Amadori product formation (reversible)
3) advanced glycosylation end product formation (AGEs) - irreversible
Pathology due to accumulation of AGEs in vessel walls

Intracellular hyperglycemia
- glucose accumulates in tissues that do not require insulin for entry: nerves, lens, kidneys, blood vessels
Metabolized to sorbitol and fructose –> osmotic load –> injury

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

DM vascular disease

A

Diabetic microangiopathy: diffuse tihckening of basement membrane, microaneurysm formation

Hyaline arteriolosclerosis: thickening of vessel walls –> HTN

Accelerated atherosclerosis: coronary arter, cerebrovascular, peripheral vascular

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

DM renal disease

A

DM most common cause of end-stage renal disease in north america
Glomerulosclerosis
Renal vascular lesion
Infections - acute/chronic pyelonephritis more common/severe in DM
Papillary necrosis - ischemic (type 1); sloughed papilla may cause obstruction
Autonomic neuropathy - urinary retention in bladder

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Glomerulosclerosis (DM)

A

Microalbuminuria - earliest clinically detectable feature
Diffuse glomerulosclerosis:
- diffuse increase in the mesangial matrix in glomerulus
-not specific

Nodular glomerulosclerosis (Kimmelstiel-Wilson lesion)

  • distinctive ball-like deposits of matrix in mesangial core of clomerulus
  • tends to occur at periphery of glomerulus pushing capillaries aside
  • presence of nodular glomerulosclerosis = DM
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Renal vascular lesions (DM)

A

renal atherosclerosis - both large and small vessels

Renal arteriolosclerosis - afferent and efferent arteriole

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Eye disease (DM)

A

diabetic retinopathy
cataracts - usually premature development of senile nuclear sclerosis and cortical cataract, not hyperglycemic cataract due to sorbitol (rare)
glaucoma - neovascularization may affect iris (rare); block drainage of aqueous fluid
ocular palsies- usually secondary to CNIII infarct; Argyll Robertson pupils and Horner’s syndrome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Diabetic retinopathy classifications

A

Background (non-proliferative)
Pre-proliferative (advanced non-proliferative)
Proliferative retinopathy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Background diabetic retinopathy

A

Increased vascular permeability and retinal ischemia (microangiopathy)
earliest features = microaneurysms (dots)
Intra-retinal hemorrhages (blots)
hemorrhage into nerve fibre layer (flame shape)
hard exudates (lipid deposits)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Pre-proliferative diabetic retinopathy

A

increased caliber and beading of retinal veins
cotton wool spots - microinfarcts of nerve fibre layer with fuzzy edges
arteriolar hyalinization (cytoid bodies)
large areas of capillary non-perfusion in absence of new vessels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Proliferative retinopathy
Ischemia and hypoxia of retina --> neovascularization fragile new vessels rupture and bleed fibrosis, then contraction causing increased traction on retina possible retinal detachment
26
DM neurologic disease
distal symmetric sensori-motor polyneuropathy Autonomic neuropathy diabetic polyradiculopathy (diabetic amyotrophy) mononeuropathy
27
Distal symmetric sensori-motor polyneuropathy
Most common neuropathy in diabetics, unknown etiology Sensori-motor nerves affected (motor effects usually less pronounced) decreased sensation in distal extremities All sensory modalities affected
28
Autonomic neuropathy - DM
ED | bowel dysfunction
29
Diabetic polyradiculopathy
uncommon, usually males with type 2 axon loss at level of nerve root (L2-L4, maybe L5) rapid development of pain, weakness of upper legs (esp. anterior thighs)
30
Mononeuropathy
single/mnultiple, peripheral or cranial nerves (compression/entrapment or infarction) asymmetric
31
DM skin disease
necrobiosis lipoidica diabeticorum (non-scaling plaque on shi nwith yellow skin, telangiectasia) granuloma annulare (lesion with raised annular border on dorsum of hand/arm) injection site lipodystrophy recurrent infections (esp Candida) ulcers
32
DM - infection
malignant otitis externa (Pseudomonas) rhinocerebral mucormycosis (increased risk if ketoacidotic) emphysematous cholecystitis emphysematous pyelonephritis/papillary necrosis mucocutaneous candidal infections soft tissue infection - diabetic foot
33
DM prevention/screening/diagnosis
Inial: fasting plasma glucose (<6.1) oGTT - higher sensitivity HbA1C (4-6%)
34
Insulin PK
based on diffusion time
35
Oral hypoglycemic agents
``` sulfonylureas meglitinides alpha-glucosidase inhibitors biguanides thiaxolindinediones incretin ```
36
Sulfonylurea MOA
Bind to SU receptors on beta cells closure of K-ATP channels --> depolarization of cell --> CaV channels open --> Ca influx --> insulin release Glucose-independent insulin release
37
Sulfonylurea PK
metabolized in liver | mostly excreted by the kidney
38
Sulfonylurea effects
improve hyperglycemia and glucotoxicity | reduces HbA1c by 1-2%
39
Sulfonylurea SEs
weight gain | hypoglycemia (esp in RF, liver failure and elderly)
40
SU prototype
-ide
41
Meglitinides MOA
insulin secretagogues Bind to K-ATP channels on beta cells Glucose-dependent insulin release
42
Meglitinide PKs
short-acting, take after meals liver metabolism 90% fecal excretion
43
meglitinide suffix
-glinide
44
meglitinide effects
attenuate post-prandial hyperglycemia | reduces HbA1c by 1-2%
45
Alpha-glucosidase inhibitor suffix
-acarbose
46
Alpha-glucosidase inhibitor MOA
decreased conversion of complex CHO to monosaccharides
47
Alpha-glucosidase inhibitor PK
excreted in feces/urine | take with meals
48
Alpha-glucosidase inhibitor effect
reduce HbA1c by 0.4-1%
49
Alpha-glucosidase inhibitor SE
weight neutral GI symptoms hypoglycemia
50
Biguanide prototype
metformin
51
Biguanide MOA
reduce hepatic gluconeogenesis increase insulin-stimulated glucose transport at muscle decrease FA oxidation
52
Biguanide PK
onset within 1-2 hour not metabolized eliminated via urine
53
Biguanide effects
reduce HbA1c by 1-2% reduces triglycerides and LDL cholesterol increases HDL reduction in MI
54
metformin SE
``` wt loss less hyperglycemia GI metallic taste lactic acidosis (rare) ```
55
Thiaxolindinedione suffix
-glitazone
56
Thiaxolindinedione MOA
enhance responsiveness and efficiency of beta cells
57
Thiaxolindinedione PK
durable monotherapy | requires 6-12 weeks for maximal effect
58
Thiaxolindinedione effects
Lowers HbA1c by 1-2% over 6-12 weeks may increase HDL and LDL, reduce TAGs may improve CV effects
59
Thiaxolindinedione SEs
weight gain fluid retention (contraindicated in CHF) rare risk of macular edema and fractures hepatotoxicity with troglitazone (less wiht newer agents)
60
GLP1 agonist suffix
-tide
61
GLP1 agonist MOA
``` incretin Actions of endogeneous GLP1: -stimulates insulin secretion - suppresses glucagon secretion -slows gastric emptying -improves insulin sensitivity -reduces food intake ```
62
GLP1 agonist PK
injected
63
GLP1 agonist effect
lowers HbA1c by 0.4-0.8%
64
GLP1 SE
potential weight loss nausea, vomiting, bloating hypoglycemia rare
65
Dipeptidyl peptidase-IV inhibitor suffix
-sitagliptin
66
Dipeptidyl peptidase-IV inhibitor MOA
inhibition of DPP-IV (breaks down GLP1)
67
DDPIV inhibitor effects
lowers HbA1C by 0.4-0.8%
68
DDPIV inhibitor Se
potential weight loss nausea vomiting bloating hypoglycemia rare
69
PKC activation
Hyperglycemia causes PKC activation (increased DAG --> PKC activated) production of VEGF, TGFB and plasminogen activator inhibitor (procoagulant)
70
Polyol path
glucose --> sorbitol --> fructose NADPH used up, required for glutathione production oxidative stress sorbitol --> cataracts